Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1-March 31, 2020
May 11, 2020 10:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so called “feeding intolerance” affecting premature...
Infant Bacterial Therapeutics publicerar årsredovisning för 2019
April 03, 2020 08:05 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2019. Årsredovisningen finns tillgänglig på IBTs hemsida ibtherapeutics.com under avsnittet ”Investerare...
Infant Bacterial Therapeutics publishes Annual Report for 2019
April 03, 2020 08:05 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) has today published the Annual Report for 2019. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media –...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 december 2019
February 11, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Vid avgivandet av denna kommuniké har IBT bedrivit patientrekrytering under drygt sju månader i den pågående kliniska fas III-studien med IBP-9414. Vi har som tidigare meddelats...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2019
February 11, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT’s ongoing clinical phase III study with IBP-9414 has, as of the date of this year-end report, conducted patient recruitment for more than seven months. We have, as...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 september 2019
November 07, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
VD Kommenterar I förra kvartalsrapporten meddelade vi att vi fick in den första patienten i vår kliniska fas III- studie. Denna studie är det operationellt mest väsentliga i IBT:s verksamhet och jag...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2019
November 07, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO In our previous quarterly report we were able to announce that the first patient had been recruited in our clinical phase III-study. This study is operationally the most...
NORBIT ASA – Continued profitable growth for the third quarter of 2019
October 29, 2019 02:00 ET
|
NORBIT ASA
Trondheim, 29 October 2019: NORBIT, a global provider of tailored technology to carefully selected niches, today reported revenues for the third quarter of 2019 of NOK 154.4 million, representing a...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2019
August 21, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2019 VD kommenterar Den 4 juli 2019 kunde vi meddela att den första patienten i IBTs kliniska fas III-studie hade...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2019
August 21, 2019 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2019 Message from the CEO On July 4 we were able to announce that the first patient had been recruited...